Evidence map›Paper›PMID 29477964›Full record

ArticleAmerican journal of ophthalmology2018

Visual Function Metrics in Early and Intermediate Dry Age-related Macular Degeneration for Use as Clinical Trial Endpoints.

Kimberly J Cocce, Sandra S Stinnett, Ulrich F O Luhmann, Lejla Vajzovic, Anupama Horne, Stefanie G Schuman, Cynthia A Toth, Scott W Cousins, Eleonora M Lad

Registry-linked trialAbstract read
In one paragraph

Article in American journal of ophthalmology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01822873 (Evaluation of Visual Function Impairments in Patients With Early Dry Age-related Macular Degeneration), which is not on this map. Cited by 79 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01822873 completednot on this map

Evaluation of Visual Function Impairments in Patients With Early Dry Age-related Macular Degeneration

TypeobservationalSponsorDuke UniversityRan2013 to 2018Enrolled128ConditionsAge Related Macular Degeneration
3 · Its place in the literature

Who cites it

79 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Observational
  6. Article
  7. Article
  8. Impaired Rod-Mediated Vision is the Functional Hallmark of Ageing and Early and Intermediate Age-Related Macular Degeneration.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2026
    Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Observational
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article

19 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kimberly J CocceDepartment of Ophthalmology, Duke University Medical Center, Durham, North Carolina.
Sandra S StinnettDepartment of Ophthalmology, Duke University Medical Center, Durham, North Carolina.
Ulrich F O LuhmannRoche Pharmaceutical Research and Early Development, Translational Medicine Neuroscience & Ophthalmology & Rare Diseases Biomarkers, Roche Innovation Center Basel, Basel, Switzerland.
Lejla VajzovicDepartment of Ophthalmology, Duke University Medical Center, Durham, North Carolina.
Anupama HorneDepartment of Ophthalmology, Duke University Medical Center, Durham, North Carolina.
Stefanie G SchumanDepartment of Ophthalmology, Duke University Medical Center, Durham, North Carolina.
Cynthia A TothDepartment of Ophthalmology, Duke University Medical Center, Durham, North Carolina.
Scott W CousinsDepartment of Ophthalmology, Duke University Medical Center, Durham, North Carolina.
Eleonora M LadDepartment of Ophthalmology, Duke University Medical Center, Durham, North Carolina. Electronic address: nora.lad@duke.edu.

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM007171 · NIGMS · DUKE UNIVERSITY · PI KONTOS, CHRISTOPHER D · 1985 to 2021
$31.2M
Monocytes in Dry Age-Related Macular DegenerationK23EY026988 · NEI · DUKE UNIVERSITY · PI LAD, ELEONORA GEORGETA · 2016 to 2018
$420k
NEI NIH HHS K23 EY026988NIGMS NIH HHS T32 GM007171
6 · The paper itself

Abstract

purposeTo evaluate and quantify visual function metrics to be used as endpoints of age-related macular degeneration (AMD) stages and visual acuity (VA) loss in patients with early and intermediate AMD.

designCross-sectional analysis of baseline data from a prospective study.

methodsOne hundred and one patients were enrolled at Duke Eye Center: 80 patients with early AMD (Age-Related Eye Disease Study [AREDS] stage 2 [n = 33] and intermediate stage 3 [n = 47]) and 21 age-matched, normal controls. A dilated retinal examination, macular pigment optical density measurements, and several functional assessments (best-corrected visual acuity, macular integrity assessment mesopic microperimety, dark adaptometry, low-luminance visual acuity [LLVA] [standard using a log 2.0 neutral density filter and computerized method], and cone contrast test [CCT]) were performed. Low-luminance deficit (LLD) was defined as the difference in numbers of letters read at standard vs low luminance. Group comparisons were performed to evaluate differences between the control and the early and intermediate AMD groups using 2-sided significance tests.

resultsFunctional measures that significantly distinguished between normal and intermediate AMD were standard and computerized (0.5 cd/m

conclusionsOur study suggests that LLVA, microperimetry, CCT, and dark adaptation may serve as functional measures differentiating early-to-intermediate stages of dry AMD.

Indexed as

Contrast SensitivityVisual Field TestsAgedAged, 80 and overCross-Sectional StudiesDark AdaptationEndpoint DeterminationFemaleGeographic AtrophyHumansMaleMiddle AgedProspective StudiesVisual AcuityVisual Fields

Identifiers

PMID29477964
PMCPMC6043161

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.